Showing 2271-2280 of 2314 results for "".
- New Type of Treatable Vertigo Identifiedhttps://modernod.com/news/new-type-of-treatable-vertigo-identified/2480140/Investigators have identified a new type of vertigo that may be treatable, according to a report in Medscape. This recurrent spontaneous vertigo (RSV) is not accompanied by neurologic symptoms and doesn’t satisfy the diagnosis
- Aerie Submits New Drug Application to FDA for Roclatanhttps://modernod.com/news/aerie-submits-new-drug-application-to-fda-for-roclatan/2480148/Aerie Pharmaceuticals announced the submission of its new drug application (NDA) to the FDA for Roclatan (netarsudil/latanoprost ophthalmic solution) .02%/.005%. Roclatan is a once-daily eye drop designed to reduce IOP in patients with glaucoma or ocular hypertension. It is a fixed dose combinati
- President Trump Outlines Plan to Lower Drug Costshttps://modernod.com/news/president-trump-outlines-plan-to-lower-drug-costs/2480151/President Donald Trump on Friday unveiled plans to increase competition in the prescription medicine market and lower patients’ out-of-pocket costs in an effort to tackle high drug prices in the US. Under the plan, dubbed American Patients First, rules preventing government programmes from
- Novartis CEO Says Drugmaker’s Deal With Trump Lawyer Was a “Mistake”https://modernod.com/news/novartis-ceo-says-drugmakers-deal-with-trump-lawyer-was-a-mistake/2480155/In an internal email sent to employees, Novartis CEO Vasant Narasimhan apologized for the $1.2-million agreement the company made with President Donald Trump’s private lawyer Michael Cohen early last year in a bid to gain insight into US healthcare policy under the new administration. <
- Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globallyhttps://modernod.com/news/alcon-cares-project-100-commits-to-reducing-cataract-blindness-globally/2480168/Alcon announced Alcon Cares Project 100, which aims to reduce cataract blindness by providing equipment to perform phaco surgeries. Alcon Cares, a foundation that oversees equipment and product donations to those in need, will give 100 rep
- Nicox Presents Scientific Data for NCX 667 at ARVOhttps://modernod.com/news/nicox-presents-scientific-data-for-ncx-667-at-arvo/2480179/Nicox announced a poster presentation highlighting scientific data for NCX 667, a novel nitric oxide (NO) donating compound, at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, one of the key scientific events in the ophthalmology calendar, being held on April
- Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at ARVOhttps://modernod.com/news/aldeyra-therapeutics-presents-dry-eye-disease-phase-2a-clinical-trial-results-at-arvo/2480191/Aldeyra Therapeutics presented the results of a randomized, double-masked, parallel-group phase 2a dry eye disease clinical trial of topical ocular reproxalap at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting. The primary objective of the trial, to select a fo
- Bausch + Lomb Will Present Scientific and Clinical Research During ARVO Meeinghttps://modernod.com/news/bausch-lomb-will-present-scientific-and-clinical-research-during-arvo-meeing/2480199/Bausch + Lomb announced that nearly a dozen scientific posters will address the results of studies featuring several of the company’s current product offerings and pipeline programs in its Consumer Health Care, Pharmaceuticals and Surgical businesses during the Association for Research in Vision
- Aerie Pharmaceuticals Joins the ASCRS Foundation in Raising Funds to Provide Eye Care for the World’s Neediest Patientshttps://modernod.com/news/aerie-pharmaceuticals-joins-the-ascrs-foundation-in-raising-funds-to-provide-eye-care-for-the-worlds-neediest-patients/2480240/Aerie Pharmaceuticals announced that it is matching, $1 for $1, the first $25,000 donated by attendees at the 2018 ASCRS-ASOA Annual Meeting, being held in Washington DC, from April 13-17, to the ASCRS Foundation’s charitable eye care programs. “The ASCRS Foundation is amplifying a long tr
- Study Shows No Benefit From Fatty Acid Supplements in Dry Eyehttps://modernod.com/news/study-shows-no-benefit-from-fatty-acid-supplements-in-dry-eye/2480241/A clinical trial supported by the National Eye Institute shows that oral omega-3 is no better than placebo in relieving signs and symptoms of dry eye disease. The Dry Eye and Assessment Management Study (DREAM) is the first large-scale real-world, double-masked, randomized clinical trial t